Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — The Trump administration came remarkably close to shoring up the scattershot way the United States regulates the “bioeconomy” — a wide-ranging category of products like lab grown meat, biofuels, DNA storage drives, and CAR-T cancer drugs — but fell short. Now, a bipartisan group of lawmakers is within striking distance of the same.

An executive order drafted by Trump’s team and obtained by STAT reveals the previous White House’s strategy. The order, which was shelved amid the coronavirus pandemic according to one Trump administration source who worked on the document, would have directed the Office of Science and Technology Policy and the National Security Council to chair an “interagency committee” that would create a national bioeconomy strategy within 210 days.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.